10:20 AM EDT, 10/06/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Monday new three-year data from its KINECT-HD2 study demonstrated once-daily Ingrezza capsules maintained long-term safety and continued to reduce chorea symptom severity of irregular and unpredictable movements in adults with Huntington's disease.

The company said the findings were presented at the 2025 MDS International Congress of Parkinson's Disease and Movement Disorders in Honolulu.

The open-label study included 154 adults treated for up to three years, Neurocrine said.

The company said treatment indicated early and sustained improvements in chorea severity and results were consistent regardless of concomitant antipsychotic use.

Safety and tolerability were assessed through treatment-emergent adverse events which were in line with the known safety profile of Ingrezza and symptoms of Huntington's disease, according to Neurocrine.

Price: 137.27, Change: +0.24, Percent Change: +0.18